(Q44750591)

English

Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics

scientific article published in April 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

3

object named as

R M Saliba

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Richard E Champlin

7

object named as

R E Champlin

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

1

object named as

I F Khouri

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Michael J. Keating

6

object named as

M J Keating

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

author name string

M Albitar

2

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

C Ippoliti

4

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Y C Ma

5

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

language of work or name

0 references

publication date

1 April 2004

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

33

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

833-837

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

The CD52 antigen and development of the CAMPATH antibodies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704435

21 January 2018

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704435

21 January 2018

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704435

21 January 2018

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704435

21 January 2018

Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704435

21 January 2018

High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704435

21 January 2018

Remission Induction in Patients with Lymphoid Malignancies Using Unconjugated CAMPATH-1 Monoclonal Antibodies.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704435

21 January 2018

Double T cell depletion of bone marrow using sequential positive and negative cell immunoaffinity or CD34+ cell selection followed by Campath-1M; effect on CD34+ cells and progenitor cell recoveries

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704435

21 January 2018

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704435

21 January 2018

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704435

21 January 2018

Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704435

21 January 2018

Humanized CD52 monoclonal antibody campath-1H as first-line treatment in chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704435

21 January 2018

Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704435

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of T-cell prolymphocytic leukemia with human CD52 antibody

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704435

7 January 2021

based on heuristic

inferred from DOI database lookup

CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704435

7 January 2021

based on heuristic

inferred from DOI database lookup

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704435

7 January 2021

based on heuristic

inferred from DOI database lookup

Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704435

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704435

7 January 2021

based on heuristic

inferred from DOI database lookup

Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704435

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1704435

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44750591&oldid=2206888566"